Multidrug-resistant tuberculosis is already a global pandemic, with focal "hot spots" of ongoing transmission. Although DOTS (directly observed treatment, short course) chemotherapy is the goal of global tuberculosis control, short-course chemotherapy will not cure multidrug-resistant tuberculosis. In settings of high transmission of multidrug-resistant tuberculosis, "DOTS plus" (a complementary DOTS-based strategy with provisions for treating multidrug-resistant tuberculosis) is warranted. DOTS-plus project implementation to date reveals important clinical, epidemiological, and economic lessons. Community-based strategies designed to enhance local capacity are cost effective and make it possible to meet new medical challenges.
No takes yet. Share an insight, caveat, or question.
Paul Farmer (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: